Literature DB >> 27349506

Dramatic Antitumor Activity of Nivolumab in Advanced HER2-Positive Lung Cancer.

Chiara Catania1, Antonio Passaro2, Elena Guerini Rocco3, Gianluca Spitaleri2, Massimo Barberis3, Cristina Noberasco2, Ester Del Signore2, Laura Travaini4, Filippo de Marinis2.   

Abstract

Entities:  

Keywords:  Activity of nivolumab; Anti-PDL1; ERBB family; Immunotherapy; Lung adenocarcinoma

Mesh：

Substances：

Year:  2016        PMID： 27349506     DOI： 10.1016/j.cllc.2016.05.004

Source DB:  PubMed          Journal:  Clin Lung Cancer        ISSN： 1525-7304            Impact factor:   4.785


× No keyword cloud information.
  4 in total

1.  The Significant Antitumor Activity of Nivolumab in Lung Adenocarcinoma with Choriocarcinomatous Features.

Authors:  Mieko Ochi; Shingo Miyamoto; Yuriko Terada; Yoshiaki Furuhata; Nobuyasu Awano; Takehiro Izumo; Soichiro Ikushima; Yuan Bae; Toshio Kumasaka; Hideo Kunito
Journal:  Intern Med       Date:  2018-02-09       Impact factor: 1.271

2.  ERBB2-Mutated Metastatic Non-Small Cell Lung Cancer: Response and Resistance to Targeted Therapies.

Authors:  Jody C Chuang; Henning Stehr; Ying Liang; Millie Das; Jane Huang; Maximilian Diehn; Heather A Wakelee; Joel W Neal
Journal:  J Thorac Oncol       Date:  2017-02-04       Impact factor: 15.609

3.  Clinical Characteristics and Outcomes of Non-small Cell Lung Cancer Patients with HER2 Alterations in Korea.

Authors:  Kangkook Lee; Hyun Ae Jung; Jong-Mu Sun; Se-Hoon Lee; Jin Seok Ahn; Keunchil Park; Myung-Ju Ahn
Journal:  Cancer Res Treat       Date:  2019-07-26       Impact factor: 4.679

4.  Efficacy of Combination Chemo-Immunotherapy as a First-Line Treatment for Advanced Non-Small-Cell Lung Cancer Patients With HER2 Alterations: A Case Series.

Authors:  Shuang Zhao; Xinghong Xian; Panwen Tian; Weimin Li; Ke Wang; Yalun Li
Journal:  Front Oncol       Date:  2021-04-20       Impact factor: 6.244
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.